Business ❯ Biotechnology

Drug Development

Clinical Trials Clinical Research Artificial Intelligence Regulatory Affairs Autoimmune Diseases AI in Healthcare Regulatory Compliance Contract Research Organizations Commercial Assets Neuro-immunology Axovant Sciences Pharmaceutical Industry Animal Health FDA Approvals Cancer Therapies Collaborations Lifespan Extension Therapies Pharmaceuticals Regulatory Approval Antibody Discovery Leadership Funding Regulatory Environment Computational Models Patent Expiration Therapeutics Market Performance

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

Management signals a reset year powered by biologics growth plus milestone income.

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

PsiThera Raises $47.5 Million and Appoints Eric Shaff as CEO to Push Oral TNF Small-Molecule Drugs

Biogen, Dayra Launch $50 Million Pact to Develop Oral Macrocyclic Peptides for Immunology

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

NRG Therapeutics Raises £50M to Advance Mitochondrial Neurodegeneration Drug Into the Clinic

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market